Cardiac complications are major limiting factors regarding the success of high-dose chemotherapy supported by blood stem cell transplantation (BSCT). The cardiotoxicity of cyclophosphamide remains obscure relative to that of anthracyclines. The aim of this study was to estimate noninvasively the cardiotoxicity of cyclophosphamide administered during the pretransplant conditioning of BSCT for patients with various hematological diseases. A total of 27 consecutive patients were divided into two groups depending on the conditioning regimen, ie, group A (n=15) which received cyclophosphamide (median dose of 120 mg/kg; range 100 to 200 mg/kg) and group B (n=12) which did not. Ultrasound cardiograms (UCG) and signal-averaged electrocardiograms (SAECG) were recorded in the two groups both preceding and following the BSCT. There were no statistical intergroup or intragroup differences in left ventricular (LV) dimensions or contractile function. Significant (P<0.01) posttransplant increases in interventricular septal wall thickness and Ap/Ep ratio were noted in group A. Moreover, the filtered QRS duration as estimated by SAECG was prolonged (P<0.05) whereas the summated LV voltage (S V1 +R V5 ) was reduced in the posttransplant period only in group A. These results suggest that early cyclophosphamide cardiotoxicity was characterized by LV diastolic rather than systolic dysfunction. These findings may contribute to acute hemodynamic deterioration observed after cyclophosphamide-containing conditioning chemotherapy. (Jpn Heart J 2002; 43: 249-261) 
experienced various cardiovascular manifestations caused by antineoplastic agents administered preparatory to the BSCT alone or in combination with cardiovascular agents. 4, 5) In this regard, anthracycline antibiotic agents are widely known to cause cumulative cardiac dysfunction leading to heart failure 6, 7) and sudden cardiac death. 8) Relative to the well-known cardiotoxicity of anthracycline, that of cyclophosphamide, an immunosuppressive and antineoplastic alkylating agent, is still obscure.
9) The aim of this investigation was therefore to estimate retrospectively, using noninvasive ultrasound cardiogram (UCG) and signal-averaged electrocardiogram (SAECG), the cardiotoxicity induced by cyclophosphamide administered to patients with various hematological diseases who underwent BSCT. We hope that this kind of study will contribute towards preventing the acute hemodynamic deterioration observed immediately after cyclophosphamide-containing chemotherapy and increasing the success rate of BSCT.
METHODS
Study patients: A total of 27 consecutive patients with various hematological diseases who underwent autologous or allogeneic BSCT between 1992 and 1995 were enrolled in the study (median age, 28 years; range, 11-57 years). The baseline characteristics of the patients are listed in Table I . Pretransplant conditioning regimens did or did not include cyclophosphamide and these were established in a clinical conference conducted by hematologists in the Department of Medicine and Biosystemic Science of Kyushu University Hospital, depending on the overall medical background such as staging and histology of malignant hematological diseases, bone marrow status, and the patients' general conditions. These hematologists explained the chemotherapeutic strategies to the patients and written informed consent was obtained from each patient prior to enrollment. Consequently, 27 patients were divided into two groups, ie, group A in which cyclophosphamide was administered with a median dose of 120 (range, 100 to 200 mg/ kg) (n=15), and group B in which this agent was not included in the pretransplant conditioning regimen (n=12). The distribution of hematological diseases, background profile including cardiovascular risk factors, the ratio of bone marrow relative to peripheral blood stem cell transplantation, the dose of other antineoplastic agents combined with cyclophosphamide, or the cumulative dose of total body irradiation did not differ between the two groups. The average time interval from the pretransplant cardiac examination to the BSCT and that from the BSCT to the posttransplant recording did not differ between the two groups (Table I) . Posttransplant examinations were conducted under a condition free from opportunistic infections and after recovery from the hematological nadir defined as a leukocyte count <1,000/µL and a platelet count <20,000/µL. UCG study: Routine M-mode recording was conducted by a left parasternal approach and pulse Doppler recording was performed under an appropriate crosssectional image guiding from the parasternal and apical windows, using a commercially available 3.5 MHz transducer. M-mode and pulse Doppler tracings were registered at a speed of 50 or 100 mm/sec on a strip-chart. The following Mmode variables were estimated; left atrial dimension (LAD), left ventricular (LV) end-diastolic and end-systolic dimension (LVDd and LVDs, respectively), and end-diastolic interventricular septal and LV posterior wall thickness (IVSd, PWd), according to the recommendations of the American Society of Echocardiography.
10) LV ejection fraction (LVEF) was estimated according to the method of Teichholz.
11) LV fractional shortening (LVFS) was calculated as [(LVDdLVDs)/LVDd] × 100 (%). In pulse Doppler flowmetry, the sampling point (4 mm in length) was located at the level of the mitral tip of the LV inflow area, with the smallest possible angle (<10°) between the ultrasound beam and presumed direction of blood flow, so that no particular angle correction was required. From the Doppler spectral tracing the following data were obtained; peak velocity (cm/sec) of early diastolic rapid filling flow (Ep component), that of atrial filling flow (Ap component) and the Ap/Ep ratio. All UCG variables were estimated by two experienced cardiologists who were unaware of the study protocol. Intraobserver variances were minimized by mutual checking and interobserver differences were resolved by a third observer. SAECG study: SAECG was recorded as a consecutive 200 sinus beat acquisition using a Megacart (Siemens Co. Ltd., Berlin, Germany) in conjunction with UCG recording on the same day. Data acquisition was conducted with a synthesized three-channel Frank-lead set (ie, X, Y, Z) under the condition that the correlation coefficient of QRS morphology identification was greater than 0.98. QRS signals were band-pass filtered with a bandwidth of 40 to 250 Hz. SAECG was illustrated in a vector magnitude fashion ( X 2 +Y 2 +Z 2 ) and QRS onset and offset were determined by a computer algorithm. Three parameters relating to ventricular late potential, such as filtered QRS duration (fQRS; msec), root mean square voltage (RMS; µV), and low amplitude signal duration (LAS; msec), were analyzed automatically and inspected. 12, 13) Data with a noise level greater than 1 µV were excluded from the analysis. Statistical methods: Continuous variables are presented as the mean±SD, and discontinuous variables as the median and range. Before computation data were checked visually by the cardiologists in a blind manner. Statistical analyses of intragroup or intergroup differences in continuous variables were performed by the two-tailed Student t test, either paired or unpaired as appropriate. system (Apple Japan Co. Ltd., Tokyo, Japan) was used for practical analyses. P<0.05 was regarded as statistically significant.
RESULTS
UCG study: Representative pretransplant and posttransplant UCG findings in a case in group A are presented in Figures 1 and 2 . M-mode and B-mode pretransplant UCG showed normal LV dimensions and LV systolic function (Figure 1,  upper) , whereas diffuse interventricular septal wall thickening and modest pericardial effusion associated with sinus tachycardia were observed after allogeneic BSCT (ie, bone marrow transplantation). Color Doppler study applied to the same case demonstrated that pretransplant diastolic flow velocities measured in the LV inflow area indicating an Ep component greater than the Ap component were reversed in the posttransplant UCG, suggesting that diastolic function was impaired after BSCT by the conditioning regimen including cyclophosphamide ( Figure 2 ). No localized LV wall asynergy was recorded.
The overall UCG data are presented in Table II . LVDd and LVDs showed no significant interval changes in either group. Likewise, the pretransplant and posttransplant intergroup comparisons of LVDd and LVDs were not statistically different. LVEF and LVFS also showed no significant interval changes or intergroup differences. However, with respect to the LV wall thickness, there was no significant pretransplant intergroup difference. IVSd increased significantly (P<0.01) by conditioning chemotherapy in group A but not in group B. This was the same in the case of Ap and the Ap/Ep ratio, ie, significant (P<0.01) posttransplant increases in peak flow velocity of atrial filling and the Ap/Ep ratio were observed only in group A. Moreover, a significant (P<0.05) intergroup difference was noted in these two UCG parameters after the conditioning chemotherapy. Slightly impaired posttransplant LV diastolic function was obtained only in group A. No localized LV wall asynergy was recorded and pericardial effusion was detected in small numbers in each group (P=NS). SAECG study: Figure 3 presents representative SAECG recordings preceding and following the conditioning regimen which included cyclophosphamide. With respect to the aforementioned three parameters, fQRS duration was slightly lengthened by this regimen. As in Table II , the parameters fQRS, RMS, and LAS showed no significant interval changes in group B, whereas a slight but significant (P<0.05) prolongation in fQRS was observed in group A. Standard ECG recorded simultaneously with SAECG showed a significant posttransplant increase (P<0.01) in heart rate (Table II) requiring inotropic agents and various kinds of arrhythmia treated with antiarrhythmic agents were not observed in the posttransplant period in either group. No statistical differences were found between the two groups in the duration and severity of the posttransplant nadir condition. We observed two instances of opportunistic infections, one of bacteremia, and three of fever of unknown origin in group A, whereas we encountered three cases of local bacterial or fungal infection in group B. Two patients in group A and one patient in group B died of these opportunistic infections. Acute graft vs. host disease (GVHD) of more than grade III 14) was not found in either group. Grade I GVHD was noted in one patient in each group, whereas there was only one grade II patient in group A. During careful follow-up until the end of 2000, eight patients in group A (53%) and six patients in group B (50%, P=NS) died of recurrence of their malignant hematological diseases. Consequently, the overall mortality rate was 67% (10/15) in group A and 58% (7/12) in group B (P=NS).
DISCUSSION
The major findings of this study are that posttransplant increases in IVSd, Ap component, and the Ap/Ep ratio in UCG and fQRS in SAECG were observed only in patients who received the conditioning regimen that included cyclophosphamide.
There have been other published reports regarding cardiotoxicity induced by cyclophosphamide. In 1971, Santos, et al 15) reported the first clinical case of fatal cardiotoxicity caused by cyclophosphamide. Since the 1970s, clinical evidence supporting the cardiotoxicity associated with cyclophosphamide administration, with doses ranging from 120 to 270 mg/kg, has been accumulating. [16] [17] [18] [19] [20] [21] [22] Such evidence includes electrocardiographic, mechanical, and histological findings; loss of summated QRS voltage, 21) impaired LV contractility 21, 22) and hemorrhagic pericarditis, interstitial myocardial edema, and focal myocardial necrosis. 18, 19, 21) However, most of the previous investigations reported cardiotoxicity induced by lethal doses of cyclophosphamide without reference to any control group. This presents a degree of ambiguity as to whether the fatal cardiac adverse effects should be attributed to cyclophosphamide per se or whether they were exaggerated by some adjuvant factors, such as irradiation, combination with other antineoplastic agents, or the cryopreservative agents used in BSCT. 9) The lack of significant reductions in LVEF and LVFS as observed in this study (Table II) is in contrast to previously published reports. 21, 22) Previous studies have demonstrated that high-dose cyclophosphamide induced refractory LV contractile failure associated with pulmonary edema and frequent pericardial effusion, [16] [17] [18] [19] [20] [21] [22] whereas this study revealed that LV diastolic but not systolic function was impaired significantly by the conditioning regimen that included cyclophosphamide. Moreover, pericardial effusion was observed in minor cases irrespective of the use of cyclophosphamide. Such a discrepancy arises in part from the dose-dependency of cyclophosphamide cardiotoxicity, as Goldberg, et al 23) emphasized. In the present study, cyclophosphamide was limited to a median dose of 120 (range, 100 to 200) mg/kg, which is a low dose relative to that in the literature. [16] [17] [18] [19] [20] [21] [22] Therefore, LV systolic as well as diastolic dysfunction might have occurred due to an increase in the dosage of cyclophosphamide.
In this study, a cyclophosphamide-induced posttransplant increase in IVSd was noted by UCG in spite of the reduced LV voltage (ie, S V1 +R V5 ), as in Table II . We speculated that these UCG findings reflect tissue edema but not hypertrophy as stated in the literature, 18, 19) since the latter should have resulted in an increase in the LV voltage, whereas cyclophosphamide has been reported to cause standard ECG voltage loss as a result of tissue edema causing partial electrical insulation 21) as observed in the present study. LV diastolic dysfunction observed only in group A is considered to be accounted for by this tissue edema, in concert with tachycardia and pericardial effusion. Early mechanical complication of tissue edema has been reported to be diastolic rather than systolic dysfunction due to an increase in myocardial stiffness. 24, 25) Currently, sophisticated UCG techniques are used to improve the visualization of cardiac microstructure. [26] [27] [28] Ultrasonic tissue characterization such as integrated backscatter and tissue harmonic imaging may have enabled us to distinguish myocardial edema from hypertrophy in more detail.
To our knowledge, this is the first investigation to report cyclophosphamide cardiotoxicity detected by means of SAECG. Cyclophosphamide-induced morphological changes as observed in UCG corresponds to the intraventricular conduction delay as estimated by the increase in fQRS in this study. Facchini, et al 29) reported that prolonged fQRS reflected subclinical LV dysfunction in patients with ventricular arrhythmias but with no evidence of underlying heart disease. So far, it is uncertain whether the cyclophosphamide-induced increase in fQRS can be explained by intraventricular conduction delay, possible tissue edema, or subclinical LV dysfunction caused by cyclophosphamide.
This retrospective case-control study does have some limitations. The preceding consolidation chemotherapy conducted to obtain hematological remission may have led to the deviations in the pretransplant cardiac function values observed. Cyclophosphamide administration was not randomly assigned but rather determined by physicians from a hematological viewpoint. Consequently, no significant pretransplant intergroup differences in the various parameters were observed. Moreover, time-dependent recovery of posttransplant cardiac functions was not taken into account, ie, a variable time interval between the BSCT and the posttransplant cardiac examinations may have resulted in the varied outcome, although no significant intergroup difference was detected. Furthermore, repetitive follow-up UCG examination may have revealed that the transient increase in IVSd was due to tissue edema, but not hypertrophy, as observed in acute myocarditis. [30] [31] [32] [33] In spite of these limitations, the present study, which provides valuable information concerning early cardiac complications induced by cyclophosphamide, may contribute in the near future to an increase in the success rate for BSCT.
In conclusion, this study suggests that cyclophosphamide, even at a median dose of 120 mg/kg, gives rise to significant mechanical and electrocardiographic adverse effects, which are characterized as impaired LV diastolic but not systolic function and prolonged intraventricular conduction time, and are important in predicting early cyclophosphamide-induced cardiotoxicity.
